Alzheimer's disease

Overview

Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia in older adults. It is defined clinically by gradual decline in memory, executive function, language and other cognitive domains, and pathologically by extracellular amyloid-β plaques and intraneuronal neurofibrillary tangles of hyperphosphorylated tau, accompanied by synaptic loss, neuroinflammation and neuronal death. The two lesions do not track the illness equally: amyloid accumulates first and correlates poorly with symptom severity, whereas tau spreads through connected regions in a stereotyped sequence that follows the clinical decline closely. Risk is dominated by age and by the ε4 allele of apolipoprotein E, which raises risk in a dose-dependent way without determining outcome; rare autosomal dominant mutations in APP, PSEN1 and PSEN2 cause early-onset disease and supplied much of the evidence for amyloid's causal role. The condition is now framed as a clinical-biological continuum spanning presymptomatic pathology, mild cognitive impairment and overt dementia rather than a purely symptom-based diagnosis.

That reframing rests on biomarkers that detect the pathology directly: amyloid and tau PET imaging, cerebrospinal fluid Aβ42/40 ratio and phosphorylated tau, and more recently plasma p-tau217, whose accuracy has begun to move diagnosis out of specialist centers. Beyond the two proteins, the biology implicates microglial activation, cellular senescence, oxidative stress, mitochondrial impairment and disturbed metabolic signaling. The intersection with metabolic disease is a prominent current theme: impaired insulin sensitivity and type 2 diabetes are associated with elevated dementia risk, and glucagon-like peptide-1 receptor agonists such as semaglutide, along with dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists such as tirzepatide, are under investigation as candidate therapies.

Treatment has recently changed in kind if not yet in degree. Cholinesterase inhibitors and memantine remain symptomatic only, while anti-amyloid monoclonal antibodies that clear plaque have shown modest slowing of decline in early disease — the first disease-modifying effect demonstrated — at the cost of amyloid-related imaging abnormalities, which are more frequent and more dangerous in ε4 homozygotes and require MRI monitoring. Tau-directed agents are in trials. The disease frequently co-occurs with or is studied against other neurodegenerative conditions, notably Parkinson's disease, and shares molecular players such as microtubule-associated protein tau (MAPT) and inflammatory mediators like tumor necrosis factor-α; computational and imaging approaches, including machine-learning analysis of MRI and bio-electrical signals, continue to be pursued for biomarker discovery and risk stratification.

Recent Publications Summary

Recent studies have explored diverse therapeutic approaches for Alzheimer's disease, with particular emphasis on traditional herbal medicines and their bioactive compounds. Multiple investigations demonstrated that formulations including Majoon-e-Boolis, Schisandra chinensis, Rosa × damascena combined with Commiphora wightii, and Kai-Xin-San improved cognitive function and reduced neuronal damage in rat models of AD 42584743Aug42086126May41812935Mar41548619Jan. These plant-based interventions generally operated through common mechanistic pathways, including reduction of oxidative stress and neuroinflammation, enhancement of dopaminergic activity, restoration of mitochondrial function, and modulation of neurotransmitter balance 42584743Aug41812935Mar41548619Jan. At the molecular level, herbal formulations frequently targeted pathways such as PI3K/AKT signaling and the folate-mitochondrial axis, while reducing amyloid-β and phosphorylated tau accumulation 42086126May41548619Jan.

Translational research efforts have focused on optimizing drug delivery and bioavailability through nanotechnology and chemical engineering approaches. kaempferol-conjugated manganese oxide nanocomposites demonstrated enhanced antioxidant capacity, reactive oxygen species reduction, amyloid-β disaggregation, and blood-brain barrier permeability compared to free kaempferol 42550339Aug. Similarly, solid lipid nanoparticles formulated from Peperomia pellucida flavonoids were developed specifically to enhance brain distribution and oral bioavailability for AD therapeutics 41238077Nov. These nanoparticle-based strategies address a fundamental challenge in AD treatment: delivering therapeutic agents across the blood-brain barrier in concentrations sufficient for neurological efficacy.

Epidemiological and mechanistic research has identified multiple risk factors and biomarkers for AD progression. Prospective cohort studies, including the large EPIC4ND initiative with up to 30 years of follow-up, are ongoing efforts to identify proteomic and genomic biomarkers predictive of future AD onset 42484778Jul. insulin sensitivity, quantified by the estimated glucose disposal rate, emerged as a predictor of AD risk in a cohort of nearly 300,000 dementia-free participants 42470526Jul. Accelerated biological aging, measured by PhenoAge, significantly increased AD risk in cardiovascular disease patients, with AD and Parkinson's disease mediating approximately 20–33% of the association between biological aging and mortality 42524837Jul. Additionally, analysis of microglial transcriptomics across multiple neurodegenerative diseases, including AD, revealed a conserved cross-disease inflammatory transcriptional program and identified SPP1 as a potential disease-spanning biomarker 42011986Apr. Emerging evidence also suggests a protective association between anti-herpetic drug exposure and AD treatment initiation, warranting further investigation 42297456Jun.

Emerging applications of artificial intelligence and digital therapeutic technologies have introduced novel diagnostic and intervention strategies for AD management. Machine learning approaches, including the CausalTCC framework, enable automated biomarker discovery from bio-electrical signals with minimal reliance on labeled data 42392133Jul, while semi-supervised deep learning models achieve robust AD classification from brain MRI with focus on clinically relevant structures such as the hippocampus and temporal lobes 42081490May. Digital music therapy platforms tailored through artificial intelligence represent a culturally adapted intervention approach for people with Alzheimer's disease 42127381May. These computational strategies complement ongoing investigations into energy compensation mechanisms, which posit that mitochondrial dysfunction and energy metabolism dysregulation constitute fundamental pathogenic hubs across multiple neurodegenerative diseases, including AD 41818703Mar. Furthermore, recent evidence suggests that glucagon-like peptide-1 receptor agonists may influence cognitive outcomes in individuals with type 2 diabetes, a recognized AD risk factor 41825212Mar.

What Changes, What Holds

1. Plant-based formulations reduce amyloid and neuroinflammation in AD models through multiple mechanistic pathways
NEW DIRECTION Herbal medicines including Majoon-e-Boolis and Kai-Xin-San represent a therapeutic avenue entirely absent from the Overview's treatment landscape. 41548619Jan41812935Mar Target shared pathways—oxidative stress, mitochondrial restoration, dopaminergic activity—but do so through botanical bioactive compounds rather than the monoclonal antibodies or tau-directed agents currently emphasized. Evidence remains preclinical (rat models); clinical translation and mechanistic selectivity remain unsettled.

2. Nanoparticle-conjugated bioactive compounds enhance blood-brain barrier penetration and amyloid disaggregation
NEW DIRECTION kaempferol-conjugated manganese oxide and flavonoid-loaded lipid nanoparticles represent engineered delivery solutions to a recognized barrier in AD therapeutics. 42550339Aug41238077Nov Rather than asking what crosses the blood-brain barrier passively, this work actively engineers transport. The strategies target known mechanisms (antioxidant, ROS reduction, amyloid-β) but introduce a delivery paradigm the Overview does not address.

3. Biological aging acceleration and emerging viral associations add layers to age-related dementia risk
NEW DIRECTION Biological aging measured by PhenoAge, independent of chronological age, emerged as a significant AD risk factor in cardiovascular disease patients, adding mechanistic depth to the Overview's statement that age dominates risk. 42524837Jul Separately, exposure to anti-herpetic drugs showed protective association with AD, suggesting viral infection may be part of the pathogenic picture 42297456Jun—a hypothesis the Overview does not raise. Both findings require confirmation before reshaping prevention strategy.

4. Bio-electrical signal machine learning and GLP-1 preliminary data refine computational and metabolic AD strategies
REINFORCES CausalTCC framework enables automated biomarker discovery from bio-electrical signals, advancing a pursuit the Overview explicitly names. 42392133Jul Preliminary evidence that GLP-1 agonists influence cognitive outcomes in type 2 diabetes validates mechanistic rationale for glucose-dependent drugs the Overview anticipates. 41825212Mar These represent refinements of existing strategic directions rather than fundamental reorientations.

Overview update candidates: none — findings remain either preclinical or too preliminary for baseline revision.